Induction of sirtuin-1 signaling by resveratrol induces human chondrosarcoma cell apoptosis and exhibits antitumor activity

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Chao, Sung Chuan ^a,b   Chen, Ying Ju ^a   Huang, Kuo How ^c   Kuo, Kuan Lin ^a,c   Yang, Ting Hua ^b   Huang, Kuo Yuan ^d   Wang, Ching Chia ^a   Tang, Chih Hsin ^e   Yang, Rong Sen ^a   Liu, Shing Hwa ^a,f  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

^f CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN KINASE R; RESVERATROL; SIRT1 PROTEIN, HUMAN; SIRTUIN 1; SMALL INTERFERING RNA;

ACETYLATION; ANIMAL; APOPTOSIS; BONE TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHONDROSARCOMA; DISEASE EXACERBATION; DRUG EFFECT; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ACETYLATION; ANIMALS; APOPTOSIS; BONE NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHONDROSARCOMA; DISEASE PROGRESSION; EIF-2 KINASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; RESVERATROL; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SIRTUIN 1; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85020620200     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-03635-7     Document Type: Article

References (54)

1. Gelderblom, H. et al. The clinical approach towards chondrosarcoma. Oncologist 13, 320-329 (2008).
2. Kato, T. et al. Metaplastic breast carcinoma with chondrosarcomatous differentiation: Fine needle aspiration cytology findings. A case report. Diagn. Cytopathol. 34, 772-775 (2006).
3. Jamil, N., Howie, S. & Salter, D. M. Therapeutic molecular targets in human chondrosarcoma. Int. J. Exp. Pathol. 91, 387-393 (2010).
4. Saiko, P., Szakmary, A., Jaeger, W. & Szekeres, T. Resveratrol and its analogs: defense against cancer, coronary disease and neurodegenerative maladies or just a fad Mutat. Res. 658, 68-94 (2008).
5. Jang, M. et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275, 218-220 (1997).
6. Frazzi, R. et al. Resveratrol mediated apoptosis of hodgkin lymphoma cells involves SIRT1 inhibition and FOXO3a hyperacetylation. Int. J. Cancer 132, 1013-1021 (2013).
7. Ulrich, S. et al. Peroxisome proliferator-activated receptor gamma as a molecular target of resveratrol induced modulation of polyamine metabolism. Cancer Res. 66, 7348-7354 (2006).
8. Björklund, M., Roos, J., Gogvadze, V. & Shoshan, M. Resveratrol induces SIRT1-and energy-stress-independent inhibition of tumor cell regrowth after low-dose platinum treatment. Cancer Chemother. Pharmacol. 68, 1459-1467 (2011).
9. Bradamante, S., Barenghi, L. & Villa, A. Cardiovascular protective effects of resveratrol. Cardiovasc. Drug Rev. 22, 169-188 (2004).
10. Sun, A. Y., Simonyi, A. & Sun, G. Y. The "French paradox" and beyond: neuroprotective effects of polyphenols. Free Radic. Biol. Med. 32, 314-318 (2002).
11. Pervaiz, S. Resveratrol: from grapevines to mammalian biology. FASEB J. 17, 1975-1985 (2003).
12. Campagna, M. & Rivas, C. Antiviral activity of resveratrol. Biochem. Soc. Trans. 38, 50-53 (2010).
13. Soleas, G. J., Diamandis, E. P. & Goldberg, D. M. Resveratrol: A molecule whose time has come And gone Clin. Biochem. 30, 91-113 (1997).
14. Soleas, G. J., Diamandis, E. P. & Goldberg, D. M. The world of resveratrol. Adv. Exp. Med. Biol. 492, 159-182 (2001).
15. Sun, N. J., Woo, S. H., Cassady, J. M. & Snapka, R. M. DNA polymerase and topoisomerase II inhibitors from Psoralea corylifolia. J. Nat. Prod. 61, 362-366 (1998).
16. Fontecave, M., Lepoivre, M., Elleingand, E., Gerez, C. & Guittet, O. Resveratrol, a remarkable inhibitor of ribonucleotide reductase. FEBS Lett. 421, 277-279 (1998).
17. Frojdo, S., Cozzone, D., Vidal, H. & Pirola, L. Resveratrol is a class IA phosphoinositide 3-kinase inhibitor. Biochem. J. 406, 511-518 (2007).
18. Howitz, K. T. et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425, 191-196 (2003).
19. Borra, M. T., Smith, B. C. & Denu, J. M. Mechanism of human SIRT1 activation by resveratrol. J. Biol. Chem. 280, 17187-17195 (2005).
20. Lakshminarasimhan, M., Rauh, D., Schutkowski, M. & Steegborn, C. Sirt1 activation by resveratrol is substrate sequence-selective. Aging 5, 151-154 (2013).
21. Jin, H. D. et al. Resveratrol inhibits chondrosarcoma via mitochondrial and PI3K/Akt signaling pathways. Chin. J. Pathophysiol. 30, 1379-1383 (2014).
22. Im, H. J. et al. Biological effects of the plant-derived polyphenol resveratrol in human articular cartilage and chondrosarcoma cells. J. Cell. Physiol. 227, 3488-3497 (2012).
23. Guarente, L. Diverse and dynamic functions of the Sir silencing complex. Nat. Genet. 23, 281-285 (1999).
24. Tanno, M., Sakamoto, J., Miura, T., Shimamoto, K. & Horio, Y. Nucleocytoplasmic shuttling of the NAD+-dependent histone deacetylase SIRT1. J. Biol. Chem. 282, 6823-6832 (2007).
25. Song, N. Y. & Surh, Y. J. Janus-faced role of SIRT1 in tumorigenesis. Ann. N. Y. Acad. Sci. 1271, 10-19 (2012).
26. Liu, T., Liu, P. Y. & Marshall, G. M. The Critical Role of the Class III Histone Deacetylase SIRT1 in Cancer. Cancer Res. 69, 1702-1705 (2009).
27. Yuan, H., Su, L. & Chen, W. Y. The emerging and diverse roles of sirtuins in cancer: A clinical perspective. Onco. Targets Ther. 8, 1399-1416 (2013).
28. Lim, J. H. et al. Sirtuin 1 modulates cellular responses to hypoxia by deacetylating hypoxia-inducible factor 1alpha. Mol. Cell 38, 864-878 (2010).
29. Cho, I. R. et al. SIRT1 inhibits proliferation of pancreatic cancer cells expressing pancreatic adenocarcinoma up-regulated factor (PAUF), a novel oncogene, by suppression of beta-catenin. Biochem. Biophys. Res. Commun. 423, 270-275 (2012).
30. Simic, P. et al. SIRT1 suppresses the epithelial-to-mesenchymal transition in cancer metastasis and organ fibrosis. Cell Rep. 3, 1175-1186 (2013).
31. Kim, E. J., Kho, J. H., Kang, M. R. & Um, S. J. Active regulator of SIRT1 cooperates with SIRT1 and facilitates suppression of p53 activity. Mol. Cell 28, 277-290 (2007).
32. Kobayashi, Y., Furukawa-Hibi, Y. & Chen, C. SIRT1 is critical regulator of FOXO-mediated transcription in response to oxidative stress. Int. J. Mol. Med. 16, 237-243 (2005).
33. Pasinetti, G. M. et al. Neuroprotective and metabolic effects of resveratrol: Therapeutic implications for Huntington's disease and other neurodegenerative disorders. Exp. Neurol. 232, 1-6 (2011).
34. Li, Y., Bäckesjö, C. M., Haldosén, L. A. & Lindgren, U. Resveratrol inhibits proliferation and promotes apoptosis of osteosarcoma cells. Eur. J. Pharmacol. 609, 13-18 (2009).
35. Kim, E. J. & Um, S. J. SIRT1: roles in aging and cancer. BMB Rep. 41, 751-756 (2008).
36. Ren, Z. et al. Resveratrol inhibits NF-B signaling through suppression of p65 and IB kinase activities. Pharmazie 68, 689-694 (2013).
37. Rosato, R. R., Almenara, J. A. & Grant, S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1. Cancer Res. 63, 3637-3645 (2003).
38. Fong, Y. C. et al. 2-Methoxyestradiol induces apoptosis and cell cycle arrest in human chondrosarcoma cells. J. Orthop. Res. 25, 1106-1114 (2007).
39. Nakata, R., Takahashi, S. & Inoue, H. Recent advances in the study on resveratrol. Biol. Pharm. Bull. 35, 273-279 (2012).
40. Gruber, J., Tang, S. Y. & Halliwell, B. Evidence for a trade-off between survival and fitness caused by resveratrol treatment of Caenorhabditis elegans. Ann. N. Y. Acad. Sci. 1100, 530-542 (2007).
41. Shimizu, T. et al. Resveratrol induces apoptosis of human malignant B cells by activation of caspase-3 and p38 MAP kinase pathways. Biochem. Pharmacol. 71, 742-750 (2006).
42. Shore, D., Squire, M. & Nasmyth, K. A. Characterization of two genes required for the position-effect control of yeast mating-type genes. Embo J. 3, 2817-2823 (1984).
43. Chen, W. Y. et al. Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell 123, 437-448 (2005).
44. Yuan, H. et al. Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis. Blood 119, 1904-1914 (2012).
45. Firestein, R. et al. The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS One 3, e2020 (2008).
46. Feng, H. et al. The expression of SIRT1 regulates the metastaticplasticity of chondrosarcoma cells by inducing epithelialmesenchymal transition. Sci. Rep. 7, 41203 (2017).
47. Jin, H. et al. Resveratrol inhibits phosphorylation within the signal transduction and activator of transcription 3 signaling pathway by activating sirtuin 1 in SW1353 chondrosarcoma cells. Mol. Med. Rep. 14, 2685-2690 (2016).
48. Chen, Y. et al. Sirtuin-3 (SIRT3), a therapeutic target with oncogenic and tumor-suppressive function in cancer. Cell Death Dis. 5, e1047 (2014).
49. Baarine, M. et al. Proapoptotic versus anti-apoptotic properties of dietary resveratrol on tumoral and normal cardiac cells. Genes Nutr. 2, 161-169 (2011).
50. Kauppinen, A., Suuronen, T., Ojala, J., Kaarniranta, K. & Salminen, A. Antagonistic crosstalk between NF-B and SIRT1 in the regulation of inflammation and metabolic disorders. Cell. Signal. 25, 1939-1948 (2013).
51. Yao, H. & Rahman, I. Perspectives on translational and therapeutic aspects of SIRT1 in inflammaging and senescence. Biochem. Pharmacol. 84, 1332-1339 (2012).
52. Oeckinghaus, A. & Ghosh, S. The NF-B family of transcription factors and its regulation. Cold Spring Harb. Perspect. Biol. 1, a000034 (2009).
53. Yeung, F. et al. Modulation of NF-B-dependent transcription and cell survival by the SIRT1 deacetylase. Embo j. 23, 2369-2380 (2004).
54. Yang et al. Leptin promotes VEGF-C production and induces lymphangiogenesis by suppressing MIR-27b in human chondrosarcoma cells. Sci. Rep. 6, 28647 (2016).